A Phase Ib Single Center, Randomized, Blinding, Parallel-controlled Clinical Trial to Evaluate the Safety and Immunogenicity of a Recombinant Hepatitis E Vaccine in Healthy Adults Aged 16 to 65 Years Old in China

Trial Profile

A Phase Ib Single Center, Randomized, Blinding, Parallel-controlled Clinical Trial to Evaluate the Safety and Immunogenicity of a Recombinant Hepatitis E Vaccine in Healthy Adults Aged 16 to 65 Years Old in China

Completed
Phase of Trial: Phase I

Latest Information Update: 10 Aug 2017

At a glance

  • Drugs Hepatitis E vaccine recombinant (Primary) ; Recombinant hepatitis E vaccine (Hecolin)
  • Indications Hepatitis E
  • Focus Adverse reactions; Pharmacodynamics
  • Most Recent Events

    • 10 Aug 2017 Results published in the Vaccine
    • 30 Aug 2016 Status changed from recruiting to completed.
    • 12 May 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top